Phaseline

Targets › ODC1

ODC1 (Ornithine decarboxylase): drug programs, companies and trials

3 programs from 2 companies in 17 trials: 8 Phase 2, 7 Phase 1, 1 Phase 4, 1 Phase 3; Oncology, Metabolic and endocrine, Immunology; next expected readout Feb 2028.

Catalyzes the first and rate-limiting step of polyamine biosynthesis that converts ornithine into putrescine, which is the precursor for the polyamines, spermidine and spermine. Polyamines are essential for cell proliferation and are implicated in cellular processes, ranging from DNA replication to apoptosis. (UniProt, P11926)

Open in Phaseline: the race on ODC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Aminex TherapeuticsAMXT 1501 Dicaprate
Ornithine decarboxylase (ODC) inhibitor
ODC1Phase 1Melanoma (Skin Cancer); Atypical Teratoid/Rhabdoid TumorFeb 2028
Aminex TherapeuticsEflornithine Hydrochloride
Ornithine decarboxylase inhibitor
ODC1Phase 1Melanoma (Skin Cancer); Type 1 Diabetes; Neuroblastoma; Medulloblastoma …Feb 2028
Orbus TherapeuticsEflornithine
Ornithine decarboxylase inhibitor
ODC1Phase 1Glioblastoma, IDH-wildtype; Hirsuitism; Colorectal Neoplasms; Prostate Cancer …–

Conditions

Neuroblastoma (3) Melanoma (Skin Cancer) (2) Atypical Teratoid/Rhabdoid Tumor (2) Type 1 Diabetes (1) Medulloblastoma (1) Osteosarcoma Recurrent (1) Glioblastoma, IDH-wildtype (1) Hirsuitism (1) Colorectal Neoplasms (1) Prostate Cancer (1) High Risk Neuroblastoma (1) Osteosarcoma (1)

Modalities

mixed (2), small molecule (1)

Companies

Aminex Therapeutics (2) Orbus Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.